Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists—a nationwide population-based cohort study based on 2010–2013 French Health Insurance data

2017 ◽  
Vol 77 ◽  
pp. 99-108 ◽  
Author(s):  
Lucie-Marie Scailteux ◽  
Sébastien Vincendeau ◽  
Frédéric Balusson ◽  
Christophe Leclercq ◽  
André Happe ◽  
...  
Keyword(s):  
Cohort Study ◽  
Health Insurance ◽  
Cardiovascular Risk ◽  
Androgen Deprivation Therapy ◽  
Gnrh Antagonist ◽  
Population Based ◽  
Androgen Deprivation ◽  
Meaningful Difference ◽  
Health Insurance Data ◽  
Insurance Data

scholarly journals MP57-11 ANDROGEN-DEPRIVATION THERAPY AND CARDIOVASCULAR RISK (ADTCR): A NATIONWIDE POPULATION-BASED COHORT STUDY

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Lucie-Marie SCAILTEUX ◽  
Sébastien VINCENDEAU ◽  
Frédéric BALUSSON ◽  
Christophe LECLERCQ ◽  
André HAPPE ◽  
...  
Keyword(s):  
Cohort Study ◽  
Cardiovascular Risk ◽  
Androgen Deprivation Therapy ◽  
Population Based ◽  
Androgen Deprivation

Cancer risk from nitrosamine-contaminated valsartan

2021 ◽  
pp. dtb-2021-000041
Keyword(s):  
Cohort Study ◽  
Health Insurance ◽  
Cancer Risk ◽  
Longitudinal Cohort Study ◽  
Health Insurance Data ◽  
Longitudinal Cohort ◽  
German Health ◽  
Insurance Data

AbstractOverview of: Gomm W, Röthlein C, Bowl K, et al. Valsartan contaminated with N-nitrosodimethylamine and cancer risk: a longitudinal cohort study with German health insurance data. Dtsch Arztebl Int 2021; 118:357–62. doi: 10.3238/arztebl.m2021.0129.

Sign in / Sign up

Export Citation Format

Share Document